NSPR Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.180

Open

1.160

VWAP

1.15

Vol

263.19K

Mkt Cap

53.86M

Low

1.120

Amount

302.67K

EV/EBITDA(TTM)

--

Total Shares

46.84M

EV

12.29M

EV/OCF(TTM)

--

P/S(TTM)

7.71

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Show More

Events Timeline

(ET)

2026-05-04

16:40:00

InspireMD Q1 Revenue $3.4M, Exceeds Expectations

2026-05-04

09:00:00

InspireMD Initiates Voluntary Recall of CGuard Prime Stent

2026-05-04

08:50:00

InspireMD Initiates Voluntary Recall of CGuard Prime 135 Delivery System

2026-05-01 (ET)

2026-05-01

16:10:00

InspireMD Receives FDA Approval for SwitchGuard Study

2026-03-18 (ET)

2026-03-18

12:00:00

Major Averages Decline Again Amid Geopolitical Risks

2026-03-18

09:00:00

U.S. Stock Futures Lower as Investors Weigh Oil Prices Against Geopolitical Risks

2026-03-18

07:10:00

Company Expects 2026 Revenue to Reach $13M to $15M

2026-03-18

07:10:00

InspireMD Q4 Revenue $3.1M Beats Expectations

News

seekingalpha

05-04seekingalpha

InspireMD Reports Q1 2026 Earnings with 120% Revenue Growth Amid FDA Challenges

stocktwits

05-01stocktwits

InspireMD Initiates New Trial and Recalls Product

Newsfilter

05-01Newsfilter

InspireMD Receives FDA Approval to Initiate CGUARDIANS III Trial

moomoo

INSPIREMD INC - RECALL DUE TO CGUARD PRIME 135 CM TECHNICAL PERFORMANCE FALLING SHORT OF EXPECTATIONS

seekingalpha

05-01seekingalpha

InspireMD to Announce Q1 Earnings on May 4th

PRnewswire

04-14PRnewswire

Purcell & Lefkowitz LLP Investigates InspireMD for Potential Fiduciary Breaches

1 Analyst Rating

Wall Street analysts forecast NSPR stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

5.00

Averages

5.00

High

5.00

Current: 0.000

Low

5.00

Averages

5.00

High

5.00

Piper Sandler

Adam Maeder

Overweight

downgrade

$4 -> $3

AI Analysis

2026-05-05

Reason

Piper Sandler

Adam Maeder

Price Target

$4 -> $3

AI Analysis

2026-05-05

downgrade

Overweight

Reason

Piper Sandler analyst Adam Maeder lowered the firm's price target on InspireMD to $3 from $4 and keeps an Overweight rating on the shares. The firm notes the company reported good Q1 results with sales of $3.4M beating its consensus-matching estimates of $2.7M. The outperformance was driven by strength in both the U.S. and outside U.S. businesses - with Q4 marking the second full quarter of the U.S. launch. Piper is updating its model post-earnings call to reflect the temporary discontinuation of U.S. commercial activity. Altogether, the firm sees the situation as manageable and there's no change to its positive view on the company's micromesh carotid stent technology.

Lake Street

Buy

downgrade

$5 -> $4

2026-05-04

Reason

Lake Street

Price Target

$5 -> $4

2026-05-04

downgrade

Buy

Reason

Lake Street lowered the firm's price target on InspireMD to $4 from $5 and keeps a Buy rating on the shares. InspireMD's voluntary recall of the CGuard Prime 135 cm delivery system is "a disappointing setback to the U.S. launch," but the issue was identified proactively and, "most importantly," is contained to the delivery system, the analyst tells investors. The fixes required for the Prime delivery system are "both manageable and necessary to position the stent for the standard-of-care adoption it deserves," the analyst added. With the product recall InspireMD withdrew its 2026 revenue guidance of $13M-$15M, adds the analyst, who reduced the firm's 2026 revenue estimate from $13M to $8.8M.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NSPR

Unlock Now

Valuation Metrics

The current forward P/E ratio for InspireMD Inc (NSPR.O) is 6.43, compared to its 5-year average forward P/E of -1.10. For a more detailed relative valuation and DCF analysis to assess InspireMD Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.10

Current PE

6.43

Overvalued PE

2.53

Undervalued PE

-4.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.49

Current EV/EBITDA

-0.54

Overvalued EV/EBITDA

0.15

Undervalued EV/EBITDA

-1.13

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

5.57

Current PS

2.48

Overvalued PS

8.81

Undervalued PS

2.33

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Intellectia · 506 candidates

Region: USRelative Vol: >= 1.50

Ticker

Name

Market Cap$

UTime Ltd

3.14M

Sobr Safe Inc

2.76M

Sadot Group Inc

2.45M

Urban One Inc

33.00M

InspireMD Inc

53.93M

Seneca Foods Corp

930.78M

penny stocks to increase price this week

Intellectia · 11 candidates

Price: $0.20 - $5.00Moving Average Relationship: PriceAboveMA20One Week Rise Prob: >= 60One Week Predict Return: >= 5.0%

Ticker

Name

Market Cap$

Prospect Capital Corp

1.37B

Maris Tech Ltd

14.13M

Carparts.Com Inc

44.40M

InspireMD Inc

77.12M

Chanson International Holding

86.92M

Borealis Foods Inc

40.14M

Whales Holding NSPR

Trading Trends

People Also Watch

Frequently Asked Questions

What is InspireMD Inc (NSPR) stock price today?

The current price of NSPR is 1.15 USD — it has decreased -0.86

What is InspireMD Inc (NSPR)'s business?

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

What is the price predicton of NSPR Stock?

Wall Street analysts forecast NSPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NSPR is5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is InspireMD Inc (NSPR)'s revenue for the last quarter?

InspireMD Inc revenue for the last quarter amounts to 3.40M USD, increased 122.24

What is InspireMD Inc (NSPR)'s earnings per share (EPS) for the last quarter?

InspireMD Inc. EPS for the last quarter amounts to -0.16 USD, decreased -27.27

How many employees does InspireMD Inc (NSPR). have?

InspireMD Inc (NSPR) has 127 emplpoyees as of May 11 2026.

What is InspireMD Inc (NSPR) market cap?

Today NSPR has the market capitalization of 53.86M USD.